By Caroline Copley ZURICH (Reuters) - Swiss drugmaker Roche hopes data published this week will show it has a viable follow-on product to help fend off cheaper competition for its best-selling cancer drug, which loses patent protection in Europe later this year. Roche is set to present full results early on Thursday of a late-stage study for its GA101 drug in chronic lymphocytic leukaemia (CLL), ahead of the American Society of Clinical Oncology annual meeting in Chicago from May 31 to June 4. ...
Courtesy of Yahoo News
No comments:
Post a Comment